NEW

Activ Surgical Announces FDA Clearance for ActivSight Intraoperative Imaging Module

Activ Surgical announced the U.S. Food and Drug Administration (FDA) 510(k) clearance of the company’s ActivSight Intraoperative Imaging Module for enhanced surgical visualization.

Metrex Surface Disinfectant Portfolio Secures EPA Approval

The U.S. Environmental Protection Agency (EPA) has approved all eight surface disinfectant products made by an infection prevention leader, Metrex, as effective against SARS-CoV-2, the novel coronavirus that causes COVID-19.

Olympus Supports Safety Actions Regarding Surgical Smoke

Olympus has announced its support of The Joint Commission’s recommended safety actions for managing the hazards of exposure to surgical smoke for health care staff in operating rooms.

Exofin Fusion Redesign Receives FDA Approval

Chemence Medical, a leader in medical cyanoacrylate devices and products, announced the U.S. Federal Drug Administration’s (FDA) 510(k) approval of the company’s redesigned exofin fusion skin closure system.

Public Meeting – Food and Drug Administration’s Communications About the Safety of Medical Devices

The U.S. Food and Drug Administration (FDA) has announced a public meeting entitled: Communications About the Safety of Medical Devices, which will be held on April 1, 2020.

During this meeting, we will:

  • Share the FDA’s current practices about medical device safety communications, including development, content, and format
  • Hear from our stakeholders—including patients, caregivers, health care providers, regulated industry, and the media—about how we can improve our safety communications to assure they receive the information they need in a timely, clear, and consistent manner.

Learn More

Important Deadlines

  • By March 4, 2020: Request special accommodations due to a disability
  • By March 18, 2020: Register to attend the meeting
  • By March 18, 2020: Request to make oral presentations
  • By June 1, 2020: Submit written comments to the docket (FDA-2020-N-0096)

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X